AIM
BCRX icon

Acrospire Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Acrospire Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-917
Closed -$5K – 160
2017
Q2 		$5K Buy
+917
New +$5.58K ﹤0.01% 1953

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Acrospire Investment Management's BCRX Position: Q3 2017 in Review

Acrospire Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2017, closing a stake of 917 shares — an estimated $5K sold.

Acrospire Investment Management first reported a position in BCRX in Q2 2017 and held it in 1 quarter. The position peaked at $5K in Q2 2017. 120 funds tracked by Wall St. Rank hold BCRX as of Q3 2017.

  • Acrospire Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 917 BioCryst Pharmaceuticals shares in Q3 2017, an estimated $5K.
  • Acrospire Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Acrospire Investment Management's BioCryst Pharmaceuticals position peaked at $5K in Q2 2017.
  • 120 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.